Previous 10 | Next 10 |
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments. Ocumension Therapeutics inv...
Looking For The Best Biotech Stocks To Watch This Week? 3 Names To Know Biotech stocks were some of the top performers on the stock market throughout 2020. With the coronavirus vaccine tailwind carrying over to 2021, investors still have their eyes peeled on the industry. Ri...
EyePoint Pharmaceuticals (EYPT) announces that China-based Ocumension Therapeutics has made a $15.7M equity investment in the company.Under the terms of the agreement, Ocumension has purchased ~3.01M shares of EyePoint’s common stock at ~$5.22/share. “This investment underscores...
WATERTOWN, Mass., Jan. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical ...
EyePoint Pharmaceuticals (EYPT) announces a royalty monetization agreement with SWK Holdings (SWKH) for royalties payable to EYPT under its license agreement with Alimera Sciences (ALIM) for ILUVIEN.EyePoint has received a one-time $16.5M payment from SWK and, in return, SWK is entitled to re...
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders, today announced a royalty mo...
EyePoint Pharmaceuticals ([[EYPT]]) announces 1-for-10 reverse stock split effective at 5:00 p.m. ET today (December 8, 2020).EyePoint's common stock will trade on the Nasdaq Global Market on a split-adjusted basis under a new CUSIP number 30233G209, with the opening of trading on Decemb...
WATERTOWN, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it will effect a 1-for-10 reverse stock split at 5:00 p.m. Easter...
EyePoint Pharmaceuticals (EYPT) has reported results from a preclinical toxicology study of EYP-1901 for wet age-related macular degeneration (wet AMD).EYP-1901 combines EyePoint’s bioerodable Durasert sustained release technology with vorolanib, a tyrosine kinase inhibitor.Results sho...
- No unexpected safety findings during the course of the study - - On track to file an IND by end of year; Phase 1 clinical trial to commence in early 2021 - WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...